Target Validation Information
Target ID T77400
Target Name CGMP-dependent3',5'-cyclic phosphodiesterase
Target Type
Clinical Trial
Drug Potency against Target (2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol Drug Info Ki = 1000 nM [527549]
BAY-60-7550 Drug Info IC50 = 4.7 nM [527549]
Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine Drug Info IC50 = 19000 nM [533684]
Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine Drug Info IC50 = 17000 nM [533684]
3-Isobutyl-1-methyl-3,9-dihydro-purine-2,6-dione Drug Info IC50 = 12000 nM [533395]
2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one Drug Info IC50 = 6000 nM [527068]
References
Ref 527549J Med Chem. 2005 May 19;48(10):3449-62.The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Ref 527549J Med Chem. 2005 May 19;48(10):3449-62.The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Ref 533684J Med Chem. 1995 Sep 1;38(18):3547-57.Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities.
Ref 533684J Med Chem. 1995 Sep 1;38(18):3547-57.Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities.
Ref 533395J Med Chem. 1985 May;28(5):537-45.A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Ref 527068Bioorg Med Chem Lett. 2004 Jun 7;14(11):2847-51.PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.